13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001482416
Total reported value
$604.3M
$604.3M
51 檔
26.4%
According to the latest 13F quarterly dataset, Sio Capital Management, LLC managed an equity portfolio of $604.3M at the end of Q3 2025, spanning 51 distinct U.S. exchange-listed positions.
Sio Capital Management, LLC executed strategic sector rebalancing during Q3 2025, establishing 18 new positions while fully exiting 21 holdings and trimming 10 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MMS | Maximus Inc | Stock-Industrials | 12.89% | -0.71% | +1.74% | |
| 2 | CELC | Celcuity Inc | Stock-Other | 9.83% | -1.27% | — | |
| 3 | SNY | Sanofi-adr | Stock-Healthcare | 6.72% | +0.91% | +200.11% | |
| 4 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 5.75% | -3.49% | +144.74% | |
| 5 | ALKS | Alkermes plc | Stock-Healthcare | 5.12% | — | — | |
| 6 | IRON | Disc Medicine Inc | Stock-Other | 4.76% | -0.60% | EXIT | |
| 7 | MRK | Merck & Co. Inc. | Stock-Healthcare | 3.77% | — | +1.93% | |
| 8 | HSIC | Henry Schein Inc | Stock-Healthcare | 3.68% | — | — | |
| 9 | CNC | Centene CORP | Stock-Healthcare | 3.50% | -0.47% | EXIT | |
| 10 | KVUE | Kenvue Inc | Stock-Consumer Staples | 3.47% | — | — | |
| 11 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.09% | -1.57% | EXIT | |
| 12 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 2.94% | +0.74% | — | |
| 13 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.93% | -0.04% | -62.77% | |
| 14 | HAE | Haemonetics Corp/mass | Stock-Other | 2.44% | -1.78% | EXIT | |
| 15 | AQST | Aquestive Therapeutics Inc | Stock-Other | 2.12% | -0.12% | +58.11% | |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.11% | — | — | |
| 17 | AVR | Anteris Technologies Global | Stock-Other | 2.02% | +4.76% | -3.61% | |
| 18 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.84% | -1.30% | EXIT | |
| 19 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.82% | +0.35% | -36.45% | |
| 20 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.39% | +0.47% | — | |
| 21 | NVCR | NovoCure Limited | Stock-Healthcare | 1.35% | — | — | |
| 22 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.29% | -1.60% | -50.65% | |
| 23 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.26% | -1.22% | EXIT | |
| 24 | TFX | Teleflex Inc | Stock-Healthcare | 1.24% | -1.63% | EXIT | |
| 25 | SLP | Simulations Plus Inc | Stock-Other | 1.22% | — | EXIT | |
| 26 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 1.12% | -0.45% | EXIT | |
| 27 | SI | Shoulder Innovations Inc | Stock-Other | 1.11% | -0.44% | EXIT | |
| 28 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.93% | +0.03% | -29.42% | |
| 29 | SEPN | Septerna Inc | Stock-Other | 0.90% | — | -67.63% | |
| 30 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.86% | +2.96% | NEW | |
| 31 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.83% | -0.04% | — | |
| 32 | ERAS | Erasca Inc | Stock-Other | 0.76% | -0.01% | EXIT | |
| 33 | VIR | Vir Biotechnology Inc | Stock-Other | 0.69% | -0.12% | — | |
| 34 | SVRA | Savara Inc | Stock-Other | 0.66% | +0.15% | — | |
| 35 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.65% | — | -36.61% | |
| 36 | ✓ | Stock-Other | 0.53% | -0.06% | EXIT | ||
| 37 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.47% | +0.05% | -36.04% | |
| 38 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.38% | -0.01% | — | |
| 39 | CNTX | Context Therapeutics Inc | Stock-Other | 0.33% | -0.34% | EXIT | |
| 40 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.26% | — | -52.28% | |
| 41 | TELA | Tela Bio Inc | Stock-Other | 0.24% | +0.02% | — | |
| 42 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.23% | — | — | |
| 43 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.15% | -0.08% | EXIT | |
| 44 | ✓ | Modular Med Inc | Stock-Other | 0.14% | — | — | |
| 45 | ✓ | Nyxoah S A | Stock-Other | 0.06% | -0.02% | EXIT | |
| 46 | BOLD | Boundless Bio Inc | Stock-Other | 0.05% | -0.03% | EXIT | |
| 47 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.04% | — | -59.83% | |
| 48 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.02% | -0.08% | EXIT | |
| 49 | NXTC | Nextcure Inc | Stock-Other | 0.02% | — | — | |
| 50 | RCKTW | Rocket Pharmaceuticals In-27 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | +5.1% | +144.74% | Add |
| 2 | IRON | Disc Medicine Inc | +3.7% | — | Add |
| 3 | MMS | Maximus Inc | +3.4% | +1.74% | Add |
| 4 | AQST | Aquestive Therapeutics Inc | +1.8% | +58.11% | Add |
| 5 | TYRA | Tyra Biosciences Inc | +0.7% | -36.45% | Add |
| 6 | ALGS | Aligos Therapeutics Inc | +0.4% | — | Add |
| 7 | ✓ | Proqr Therapeutics N.v. | +0.3% | — | Add |
| 8 | IDYA | Ideaya Biosciences Inc | +0.3% | — | Add |
| 9 | OVID | Ovid Therapeutics Inc | +0.3% | -36.04% | Trim |
| 10 | ERAS | Erasca Inc | +0.2% | — | Add |
| 11 | BMRN | Biomarin Pharmaceutical Inc | +0.1% | — | Add |
| 12 | CNTX | Context Therapeutics Inc | +0.1% | — | Add |
| 13 | SVRA | Savara Inc | +0.1% | — | Add |
| 14 | AVTX | Avalo Therapeutics Inc | +0.1% | — | Add |
| 15 | ✓ | Modular Med Inc | +0.1% | — | Add |
| 16 | FHTX | Foghorn Therapeutics Inc | 0% | — | Add |
| 17 | TELA | Tela Bio Inc | 0% | — | Add |
| 18 | 430 | Terns Pharmaceuticals Inc | 0% | — | Add |
| 19 | HUMAW | Humacyte Inc-cw27 | 0% | — | Unchanged |
| 20 | RCKTW | Rocket Pharmaceuticals In-27 | 0% | — | Unchanged |
| 21 | BOLD | Boundless Bio Inc | 0% | — | Add |
| 22 | ✓ | Nyxoah S A | -0.1% | — | Unchanged |
| 23 | HAE | Haemonetics Corp/mass | -0.1% | — | Add |
| 24 | APRE | Aprea Therapeutics Inc | -0.1% | -59.83% | Trim |
| 25 | VIR | Vir Biotechnology Inc | -0.2% | — | Add |
| 26 | VTYXUSD | Ventyx Biosciences Inc | -0.2% | -36.61% | Trim |
| 27 | PMVP | Pmv Pharmaceuticals Inc | -0.3% | -29.42% | Trim |
| 28 | ANIP | Ani Pharmaceuticals Inc | -0.5% | -50.65% | Trim |
| 29 | SEPN | Septerna Inc | -0.5% | -67.63% | Trim |
| 30 | AVR | Anteris Technologies Global | -0.6% | -3.61% | Trim |
| 31 | DRUG | Bright Minds Biosciences Inc | -2.5% | -62.77% | Trim |
| 32 | TFX | Teleflex Inc | -3.2% | — | Trim |
| 33 | MRK | Merck & Co. Inc. | -3.5% | +1.93% | Trim |
| 34 | CELC | Celcuity Inc | — | NEW | New buy |
| 35 | ICLR | ICON Public Limited Company | — | EXIT | Sold out |
| 36 | SNY | Sanofi-adr | — | NEW | New buy |
| 37 | ZBH | Zimmer Biomet Holdings Inc | — | EXIT | Sold out |
| 38 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 39 | ALKS | Alkermes plc | — | NEW | New buy |
| 40 | LH | Labcorp Holdings Inc | — | EXIT | Sold out |
| 41 | GMED | Globus Medical Inc - A | — | EXIT | Sold out |
| 42 | HSIC | Henry Schein Inc | — | NEW | New buy |
| 43 | EMBC | Embecta CORP | — | EXIT | Sold out |
| 44 | CNC | Centene CORP | — | NEW | New buy |
| 45 | KVUE | Kenvue Inc | — | NEW | New buy |
| 46 | GSK | Gsk Plc-spon Adr | — | NEW | New buy |
| 47 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 48 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 49 | ANNX | Annexon Inc | — | EXIT | Sold out |
| 50 | TARA | Protara Therapeutic Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sio Capital Management, LLC reported a total U.S. public equity portfolio value of $604.3M across 51 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MMS, CELC, SNY) accounted for 26.4% of total reported equity market value during Q3 2025.
Top New Position Initiated
CELC
市值: $38.9M
Top Position Liquidated / Trimmed
ICLR
前期市值: $35.6M
During Q3 2025, Sio Capital Management, LLC's top holdings by market value included MMS (12.9%)、CELC (9.8%)、SNY (6.7%). The largest single position, MMS, represented 12.9% of total portfolio value.
In Q3 2025, Sio Capital Management, LLC made 69 total portfolio adjustments, initiating 18 new buys, adding to 20 positions, trimming 10 holdings, and fully liquidating 21 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.